Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Clinical pharmacology and therapeutics - 1 Oct 2005

Kajosaari Lauri I, Niemi Mikko, Neuvonen Mikko, Laitila Jouko, Neuvonen Pertti J, Backman Janne T

Abstract excerpt

BACKGROUND AND OBJECTIVE: Repaglinide is an antidiabetic drug metabolized by cytochrome P450 (CYP) 2 C 8 and 3A4, and it appears to be a substrate of the hepatic uptake transporter organic anion transporting polypeptide 1B1 (OATP1B1). We studied the effects of cyclosporine (INN, ciclosporin), an inhibitor of CYP3A4 and OATP1B1, on the pharmacokinetics and pharmacodynamics of repaglinide. METHODS: In a randomized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cross-Over Studies
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C8

Share to Liver-Specific Organic Anion Transporter 1

Share to Microsomes, Liver

Share to Organic Anion Transporters

Share to Piperidines

Source

Identifiers

PMID: 16198658
DOI: 10.1016/j.clpt.2005.07.005

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyclosporine markedly raises the plasma concentrations of repaglinide.PMID 16198658Read ↗

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Semantic proximity Read ↗

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.Semantic proximity Read ↗

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.Semantic proximity Read ↗

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.Semantic proximity Read ↗

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.Semantic proximity Read ↗

Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Semantic proximity Read ↗

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Semantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Semantic proximity Read ↗

The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.